Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.
How it helps
HBW Insight gives you the power to go behind the news stories to understand the implications of worldwide industry developments across three different but complementary consumer healthcare sectors, on your business.
How it works
A broad network of global expert analysts and journalists give you an insider’s perspective from tracking market events and their impacts from around the globe, to understand the potential impact of developments and trends. Plus, access to exclusive interviews with key opinion leaders and market movers. We also draw on the strength and expertise of the rest of the Pharma Intelligence family of analytical and market intelligence tools.
Health:
In-depth coverage and analysis of:
Beauty:
News and emerging issues in this rapidly evolving global sector on:
Wellness:
Up-to-the-minute news and the informed perspective on:
HBW Insight
By Ryan Nelson 14 Jan 2022
Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.
HBW Insight
By Malcolm Spicer 19 Nov 2021
It was only after prolonged litigation led a federal judge in 2013 to order FDA not to allow political interference with its science-based decisions that Plan B and generic equivalents became available OTC without age restrictions. “Hopefully, all I can say, it won't happen again,” says reproductive rights advocate Kirsten Moore.
HBW Insight
By Ryan Nelson 18 Nov 2021
The Environmental Protection Agency does not have the jurisdiction to grant William D. Bush’s request, even if the petitioner had specified the “chemical mixtures” he wants banned or provided the level of data required to initiate proceedings under the Toxic Substances Control Act.
HBW Insight
By Malcolm Spicer 31 Oct 2021
While working to improve the quality of VMS products available in the US and to provide information on the products to consumers, the ODS doesn’t have authority to impose change on the industry or in the marketplace.
HBW Insight
By Ryan Nelson 08 Oct 2021
At NAD 2021, Adam Waheed, an award-winning content creator with more than 17m social media followers, addressed challenges and legal risks that have escalated in recent years as influencer marketing opportunity exploded in the US and abroad.
HBW Insight
By David Ridley 13 Sep 2021
Amazon is becoming an increasingly important retail channel for the German wellness market. An analysis of best-selling categories, Omega 3, vitamin B and probiotic supplements, by Sempora Consulting suggests a mixture of exclusive and hybrid selling strategies can deliver results.
HBW Insight
By Malcolm Spicer 10 Sep 2021
Perrigo is the top potential marketer of the first OTC oral contraceptive in the US by acquiring HRA Pharma, which is preparing a switch NDA and earlier in 2021 gained UK regulatory approval for pharmacy sales of a progestin-only contraceptive, desogestrel.
HBW Insight
By Ryan Nelson 17 Aug 2021
The agency’s recent request for contractor quotes cites infants and children, people of color, and immunosuppressed individuals among users whose “unique biological characteristics” could require special consideration in the evaluation of cosmetic ingredients. The FDA also is interested in accounting for unique physicochemical aspects of ingredients such as engineered nanomaterials.
HBW Insight
By Malcolm Spicer 13 Aug 2021
Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.
HBW Insight
By Lauren Nardella 12 Aug 2021
The Germany-based firm exceeded pre-pandemic sales levels in the fiscal 2021 second half, but rising costs could slow its momentum. Coppertone was a key growth driver in the second quarter, and Beiersdorf aims to capitalize with fresh innovation, new packaging and other updates to the brand.
HBW Insight
By Malcolm Spicer 09 Jul 2021
Supplement OWL advisory board members Guru Ramanathan and Russ Michelson answer HBW Insight questions about the site’s progress and the potential for mandatory registration for dietary supplements sold in the US.
HBW Insight
By David Ridley 05 Jul 2021
“We are actively researching how to be the first OTC pharmaceutical firm to have a blister strip that satisfies regulations that is also recyclable,” reveals Perrigo's sustainability chief Steve Ramus in an exclusive interview with HBW Insight. Ramus also talks about the importance of being genuine when approaching ESG strategy.
HBW Insight
By Tom Gallen 11 Jun 2021
Bayer has launched a dedicated Consumer Health business in India to market products in key OTC categories. The company is also working to bring different stakeholders together through the creation of a new organization dedicated to promoting self-care in the South Asian country.
HBW Insight
By Eileen Francis 11 Jun 2021
New York legislation to restrict sales of weight loss and sports nutrition supplements to minors failed without reaching a vote before the end of the session. But the proposal will continue to be a challenge for industry in New York as well as around the country.
HBW Insight
By Eileen Francis 26 May 2021
Senate bill provision allowing FDA to develop unique labeling and packaging for cannabinoid supplements and foods is unnecessary, as the products should following existing labeling regulations, says CRN chief Steve Mister.
HBW Insight
02 Jun 2023
HBW Insight
02 Jun 2023
HBW Insight
02 Jun 2023
HBW Insight
01 Jun 2023
HBW Insight
01 Jun 2023
HBW Insight
31 May 2023
HBW Insight
31 May 2023
HBW Insight
31 May 2023
HBW Insight
31 May 2023
HBW Insight
30 May 2023
HBW Insight
30 May 2023
HBW Insight
29 May 2023
HBW Insight
26 May 2023
HBW Insight
26 May 2023
HBW Insight
25 May 2023
Richard specializes in
30+ years of experience
Washington DC
Eileen specializes in
23+ years of experience
Ryan specializes in
19+ years of experience
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
